Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ARGX |
---|---|---|
09:32 ET | 7883 | 473.89 |
09:34 ET | 2003 | 475.33 |
09:36 ET | 10250 | 477.55 |
09:38 ET | 600 | 478.77 |
09:39 ET | 200 | 479.15 |
09:41 ET | 500 | 480.65 |
09:43 ET | 400 | 479.605 |
09:45 ET | 2494 | 480.1 |
09:48 ET | 300 | 480.02 |
09:50 ET | 1688 | 480 |
09:52 ET | 600 | 479.49 |
09:54 ET | 200 | 479.525 |
09:56 ET | 10651 | 480.73 |
09:57 ET | 100 | 480.72 |
09:59 ET | 170 | 481.58 |
10:01 ET | 900 | 482.99 |
10:03 ET | 700 | 482.355 |
10:06 ET | 316 | 482.93 |
10:08 ET | 1900 | 481.785 |
10:10 ET | 400 | 481.22 |
10:12 ET | 300 | 481.94 |
10:14 ET | 100 | 481.64 |
10:15 ET | 884 | 481.605 |
10:17 ET | 3580 | 481.06 |
10:19 ET | 1950 | 481.26 |
10:21 ET | 3409 | 480.25 |
10:24 ET | 741 | 480.34 |
10:26 ET | 2150 | 481.4 |
10:28 ET | 500 | 480.61 |
10:30 ET | 300 | 480.39 |
10:32 ET | 3927 | 480.09 |
10:33 ET | 400 | 480.01 |
10:35 ET | 600 | 480.01 |
10:37 ET | 2305 | 479.96 |
10:39 ET | 1322 | 481.52 |
10:42 ET | 800 | 481.31 |
10:44 ET | 300 | 481.56 |
10:46 ET | 900 | 482.41 |
10:48 ET | 1925 | 481.65 |
10:50 ET | 2009 | 481.58 |
10:51 ET | 1000 | 480.805 |
10:53 ET | 1899 | 481.23 |
10:55 ET | 964 | 481.54 |
10:57 ET | 1100 | 481.19 |
11:00 ET | 300 | 481.355 |
11:02 ET | 600 | 482.375 |
11:04 ET | 1313 | 483.39 |
11:06 ET | 1700 | 482.915 |
11:08 ET | 600 | 482.995 |
11:09 ET | 2400 | 483.86 |
11:11 ET | 600 | 484.695 |
11:13 ET | 15905 | 488.96 |
11:15 ET | 10893 | 486.92 |
11:18 ET | 1402 | 485.88 |
11:20 ET | 1311 | 486.53 |
11:22 ET | 600 | 487.51 |
11:24 ET | 500 | 487.415 |
11:26 ET | 1100 | 488.77 |
11:27 ET | 2356 | 490.62 |
11:29 ET | 1200 | 490.59 |
11:31 ET | 600 | 491.31 |
11:33 ET | 700 | 491.315 |
11:36 ET | 13898 | 491.835 |
11:38 ET | 1103 | 493.185 |
11:40 ET | 300 | 493.325 |
11:42 ET | 200 | 494.085 |
11:44 ET | 200 | 493.855 |
11:45 ET | 200 | 494.17 |
11:47 ET | 6015 | 493.25 |
11:49 ET | 200 | 492.87 |
11:51 ET | 400 | 493.485 |
11:54 ET | 100 | 492.235 |
11:56 ET | 100 | 492.38 |
11:58 ET | 600 | 492.6 |
12:00 ET | 200 | 494.29 |
12:02 ET | 2286 | 492.595 |
12:03 ET | 1700 | 492.075 |
12:05 ET | 200 | 492.06 |
12:07 ET | 220 | 492.065 |
12:12 ET | 200 | 492.07 |
12:14 ET | 708 | 492.04 |
12:16 ET | 502 | 491.89 |
12:18 ET | 1938 | 491.99 |
12:20 ET | 838 | 491.435 |
12:21 ET | 677 | 491.61 |
12:23 ET | 500 | 491.865 |
12:25 ET | 869 | 494.055 |
12:27 ET | 3922 | 493.8 |
12:30 ET | 2956 | 491.75 |
12:32 ET | 300 | 491.575 |
12:34 ET | 25300 | 491.49 |
12:36 ET | 445 | 491.235 |
12:38 ET | 1644 | 492.61 |
12:39 ET | 400 | 492.9 |
12:41 ET | 953 | 492.31 |
12:43 ET | 100 | 491.75 |
12:45 ET | 213 | 492.795 |
12:50 ET | 903 | 491.935 |
12:52 ET | 100 | 491.935 |
12:54 ET | 2900 | 491.98 |
12:56 ET | 4752 | 492.08 |
12:57 ET | 6079 | 492 |
12:59 ET | 4681 | 492 |
01:01 ET | 626 | 492 |
01:03 ET | 342 | 492.105 |
01:06 ET | 300 | 491.77 |
01:08 ET | 5397 | 491.93 |
01:10 ET | 24115 | 491.145 |
01:12 ET | 9234 | 490.95 |
01:14 ET | 5300 | 491.05 |
01:15 ET | 5194 | 492 |
01:17 ET | 700 | 492.44 |
01:19 ET | 400 | 492.35 |
01:21 ET | 100 | 492.92 |
01:24 ET | 615 | 492.76 |
01:26 ET | 205 | 492.6 |
01:28 ET | 500 | 492.345 |
01:30 ET | 1000 | 492 |
01:32 ET | 100 | 492 |
01:33 ET | 3700 | 492.05 |
01:35 ET | 9497 | 492.3 |
01:37 ET | 1766 | 492.45 |
01:39 ET | 200 | 492.035 |
01:42 ET | 600 | 492 |
01:44 ET | 500 | 491.945 |
01:46 ET | 123 | 492.73 |
01:48 ET | 150 | 492.33 |
01:50 ET | 200 | 492.5 |
01:51 ET | 400 | 493.48 |
01:53 ET | 300 | 493.835 |
01:57 ET | 121 | 494.37 |
02:00 ET | 300 | 493.69 |
02:02 ET | 400 | 493.46 |
02:04 ET | 1520 | 493.795 |
02:06 ET | 1100 | 492.63 |
02:08 ET | 200 | 492.89 |
02:09 ET | 313 | 492.815 |
02:11 ET | 200 | 493.52 |
02:13 ET | 636 | 493.355 |
02:15 ET | 3406 | 494.15 |
02:18 ET | 4487 | 492.29 |
02:20 ET | 2926 | 491.345 |
02:22 ET | 500 | 491.62 |
02:24 ET | 1000 | 492.34 |
02:26 ET | 100 | 492.215 |
02:27 ET | 300 | 492.87 |
02:29 ET | 349 | 492.74 |
02:31 ET | 361 | 492.27 |
02:33 ET | 653 | 492.665 |
02:36 ET | 2110 | 492.26 |
02:38 ET | 711 | 492.965 |
02:40 ET | 600 | 493.335 |
02:42 ET | 800 | 492.93 |
02:44 ET | 1700 | 493.11 |
02:45 ET | 708 | 493.715 |
02:47 ET | 400 | 493.37 |
02:49 ET | 415 | 493.37 |
02:51 ET | 700 | 493.4325 |
02:56 ET | 2251 | 492.675 |
02:58 ET | 4300 | 491.4 |
03:00 ET | 3144 | 491.945 |
03:02 ET | 2111 | 492.18 |
03:03 ET | 400 | 492.07 |
03:05 ET | 100 | 492.09 |
03:07 ET | 400 | 492.01 |
03:09 ET | 500 | 492.01 |
03:12 ET | 5790 | 491.965 |
03:14 ET | 15241 | 491.02 |
03:16 ET | 30704 | 491 |
03:18 ET | 6034 | 489.535 |
03:20 ET | 2300 | 490.33 |
03:21 ET | 379 | 490.49 |
03:23 ET | 1438 | 491.85 |
03:25 ET | 400 | 491.74 |
03:27 ET | 600 | 491.88 |
03:30 ET | 996 | 492.13 |
03:32 ET | 1400 | 492.82 |
03:34 ET | 1097 | 492.5 |
03:36 ET | 300 | 492.95 |
03:38 ET | 4047 | 492.765 |
03:39 ET | 1195 | 493.04 |
03:41 ET | 1276 | 492.945 |
03:43 ET | 900 | 492.49 |
03:45 ET | 2378 | 492.685 |
03:48 ET | 2000 | 493.295 |
03:50 ET | 2553 | 492.81 |
03:52 ET | 6037 | 493.17 |
03:54 ET | 7073 | 492.9 |
03:56 ET | 20573 | 493.95 |
03:57 ET | 12693 | 493.94 |
03:59 ET | 16354 | 494.46 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
argenx SE | 28.8B | -142.1x | --- |
Alnylam Pharmaceuticals Inc | 30.1B | -86.7x | --- |
Sarepta Therapeutics Inc | 13.9B | 1,810.5x | --- |
Bio-Techne Corp | 12.4B | 64.1x | +23.61% |
Neurocrine Biosciences Inc | 14.7B | 40.3x | +62.04% |
Beigene Ltd | 17.4B | -21.5x | --- |
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.8B |
---|---|
Revenue (TTM) | $1.6B |
Shares Outstanding | 59.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.62 |
EPS | $-3.48 |
Book Value | $69.22 |
P/E Ratio | -142.1x |
Price/Sales (TTM) | 17.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -22.17% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.